Treatment With Erythropoietin and Cognition During Hypoglycaemia

Completed 11 enrolled Hillerod Hospital, Denmark Aarhus University Hospital · collab Erasmus Medical Center · collab Maastricht University Medical Center · collab Rigshospitalet, Denmark · collab Steno Diabetes Center Copenhagen · collab

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of the trial is to determine if erythropoietin (EPO) can enhance cognitive function during hypoglycaemia in patients with type 1 diabetes. Patients with type 1 diabetes will receive one injection of EPO. Hypoglycaemia will be induced 6 days after. Before (1 hour), during and after (1 hour) hypoglycaemia, the cognitive function will be measured.

Timeline

Start: 2008-05
Primary completion: 2009-12
Completion: 2010-12

Outcome

Met primary endpoint

paper Compared with placebo, EPO treatment was associated with a significant reduction in errors in the most complex reaction time task (-4.7 (-8.1 to -1.3), p = 0.01) PMID 23577069 ↗

Publications

Kristensen PL, Pedersen-Bjergaard U, Kjaer TW, Olsen NV, Dela F, Holst JJ, Faber J, Tarnow L, Thorsteinsson B. Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with type 1 diabetes mellitus: a randomized cross-over trial. PLoS One. 2013;8(4):e59672. doi: 10.1371/journal.pone.0059672. Epub 2013 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	epoetin alfa	Protein / enzyme biologic	40000 iu	Intravenous